Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors
January 24 2019 - 7:00AM
Emergent BioSolutions Inc. (NYSE:EBS) today announced the
appointment of Robert G. Kramer, Sr. to the company’s Board of
Directors. Mr. Kramer currently serves as Emergent’s president and
COO. Effective April 1, 2019, Mr. Kramer will assume the role of
president and CEO and will serve on the Emergent Board, succeeding
Daniel J. Abdun-Nabi and filling the vacancy created by Mr.
Abdun-Nabi’s retirement.
Fuad El-Hibri, executive chairman of the board of Emergent
BioSolutions, stated, “Bob embodies Emergent’s past and future. No
one knows Emergent more intimately than Bob does, which will serve
him well as he plays a pivotal role in taking the company to the
next level. Following the rapid expansion we have experienced in
the last few years, Bob’s appointment to the Emergent Board is a
natural progression that will ensure both a seamless leadership
transition when Dan retires and continued momentum for growth of
the company.”
“Having been part of Emergent’s management team for the last two
decades, it has been a pleasure to work with Emergent’s Board of
Directors in steering the company to where it is today, grounded by
its mission – to protect and enhance life – and guided by its focus
on public health,” said Mr. Kramer. “It continues to be a
remarkable journey and I look forward, come April, to serving in a
new capacity as member of the board with such distinguished
colleagues.”
Mr. Kramer was appointed Emergent’s president and COO in March
2018. Prior to his current position, Mr. Kramer served as EVP and
CFO from September 2012. Mr. Kramer first joined Emergent in 1999
as its CFO. From 1999 until his retirement in 2010, he held various
executive positions with the last being president of Emergent
Biodefense Operations Lansing. Mr. Kramer returned to the company
in 2011 as the interim head of the biosciences division, and then
as interim executive vice president, corporate services division.
Prior to joining Emergent in 1999, Mr. Kramer held various
financial management positions at Pharmacia Corporation, which
subsequently merged with the Upjohn Company in 1995 and eventually
became part of Pfizer Inc. Mr. Kramer received an M.B.A. from
Western Kentucky University and a B.S. in industrial management
from Clemson University.
About Emergent BioSolutionsEmergent
BioSolutions Inc. is a global life sciences company seeking to
protect and enhance life by focusing on providing specialty
products for civilian and military populations that address
accidental, deliberate, and naturally occurring public health
threats. We aspire to be a Fortune 500 company recognized for
protecting and enhancing life, driving innovation, and living our
values. Additional information about the company may be found
at www.emergentbiosolutions.com. Find us on LinkedIn and
follow us on Twitter @emergentbiosolu and Instagram
@life_at_emergent.
Investor Contact:Robert G.
BurrowsVice President, Investor
Relations240-631-3280BurrowsR@ebsi.com
Media Contact:Lynn KiefferVice
President, Corporate Communications
240-631-3391KiefferL@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Jul 2023 to Jul 2024